Is Intraoperative Parathyroid Monitoring During Minimally Invasive Parathyroidectomy Still Justified?

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Aug 6

PMID 39104811

Authors

Lindsay Hargitai

Daniela Boryshchuk

Melisa Arikan

Teresa Binter

Christian Scheuba

Philipp Riss

Affiliations

Soon will be listed here.

Abstract

Introduction: Primary hyperparathyroidism (PHPT) is the third most common endocrine disease. With parathyroidectomy, a cure rate of over 95% at initial surgery is reported. Localization of the abnormal parathyroid gland is critical for the operation to be successful. The aim of this study is to analyze data of patients with single gland disease (SGD) and positive concordant localization imaging undergoing minimally invasive parathyroidectomy (MIP) and intraoperative parathyroid hormone monitoring (IOPTH) to evaluate if IOPTH is still justified in patients with localized SGD.

Methods: A retrospective database analysis of all minimally invasive operations with IOPTH for PHPT and positive concordant localization in ultrasound (US) and Tc-sestamibi scintigraphy (MIBI) between 2016-2021. When both US and MIBI were negative, patients underwent either choline or methionine PET-CT. The patients were also analyzed a second time without applying IOPTH.

Results: In total, 198 patients were included in the study. The sensitivity of US, MIBI and PET-CT was 96%, 94% and 100%, respectively. Positive predictive value was 88%, 89% and 94% with US, MIBI and PET-CT, respectively. IOPTH was true positive in 185 (93.4%) patients. In 13 (6.6%) patients, no adequate IOPTH decline was observed after localizing and extirpating the assumed enlarged parathyroid gland. Without IOPTH, the cure rate decreased from 195 (98.5%) to 182 (92%) patients and the rate of persisting disease increased from 2 (1.0%) to 15 (7.5%) patients.

Conclusion: Discontinuing IOPTH significantly increases the persistence rate by a factor of 7.5 in patients with concordantly localized adenoma. Therefore, IOPTH appears to remain necessary even for this group of patients.

References

Barczynski M, Golkowski F, Konturek A, Buziak-Bereza M, Cichon S, Hubalewska-Dydejczyk A . Technetium-99m-sestamibi subtraction scintigraphy vs. ultrasonography combined with a rapid parathyroid hormone assay in parathyroid aspirates in preoperative localization of parathyroid adenomas and in directing surgical approach. Clin Endocrinol (Oxf). 2006; 65(1):106-13. DOI: 10.1111/j.1365-2265.2006.02556.x. View

Chen H, Pruhs Z, Starling J, Mack E . Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy. Surgery. 2005; 138(4):583-7. DOI: 10.1016/j.surg.2005.06.046. View

Wilhelm S, Wang T, Ruan D, Lee J, Asa S, Duh Q . The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016; 151(10):959-968. DOI: 10.1001/jamasurg.2016.2310. View

Riss P, Scheuba C, Asari R, Bieglmayer C, Niederle B . Is minimally invasive parathyroidectomy without QPTH monitoring justified?. Langenbecks Arch Surg. 2009; 394(5):875-80. DOI: 10.1007/s00423-009-0505-9. View

Prager G, Czerny C, Ofluoglu S, Kurtaran A, Passler C, Kaczirek K . Impact of localization studies on feasibility of minimally invasive parathyroidectomy in an endemic goiter region. J Am Coll Surg. 2003; 196(4):541-8. DOI: 10.1016/S1072-7515(02)01897-5. View

Vaghaiwalla T, Armstrong V, Saghira C, Lew J . Operative success is achieved regardless of ioPTH criterion used during focused parathyroidectomy for sporadic primary hyperparathyroidism. Am J Surg. 2023; 226(5):604-608. DOI: 10.1016/j.amjsurg.2023.06.031. View

Stalberg P, Sidhu S, Sywak M, Robinson B, Wilkinson M, Delbridge L . Intraoperative parathyroid hormone measurement during minimally invasive parathyroidectomy: does it "value-add" to decision-making?. J Am Coll Surg. 2006; 203(1):1-6. DOI: 10.1016/j.jamcollsurg.2006.03.022. View

Bergenfelz A, Hellman P, Harrison B, Sitges-Serra A, Dralle H . Positional statement of the European Society of Endocrine Surgeons (ESES) on modern techniques in pHPT surgery. Langenbecks Arch Surg. 2009; 394(5):761-4. DOI: 10.1007/s00423-009-0533-5. View

Riss P, Kaczirek K, Heinz G, Bieglmayer C, Niederle B . A "defined baseline" in PTH monitoring increases surgical success in patients with multiple gland disease. Surgery. 2007; 142(3):398-404. DOI: 10.1016/j.surg.2007.05.004. View

10.

Barczynski M, Cichon S, Konturek A, Cichon W . Minimally invasive video-assisted parathyroidectomy versus open minimally invasive parathyroidectomy for a solitary parathyroid adenoma: a prospective, randomized, blinded trial. World J Surg. 2006; 30(5):721-31. DOI: 10.1007/s00268-005-0312-6. View

11.

Bilezikian J, Khan A, Silverberg S, Fuleihan G, Marcocci C, Minisola S . Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022; 37(11):2293-2314. DOI: 10.1002/jbmr.4677. View

12.

Silva B, Cusano N, Bilezikian J . Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018; 32(5):593-607. DOI: 10.1016/j.beem.2018.09.004. View

13.

Medas F, Cappellacci F, Canu G, Noordzij J, Erdas E, Calo P . The role of Rapid Intraoperative Parathyroid Hormone (ioPTH) assay in determining outcome of parathyroidectomy in primary hyperparathyroidism: A systematic review and meta-analysis. Int J Surg. 2021; 92:106042. DOI: 10.1016/j.ijsu.2021.106042. View

14.

Araz M, Soydal C, Ozkan E, Kir M, Ibis E, Gullu S . The efficacy of fluorine-18-choline PET/CT in comparison with 99mTc-MIBI SPECT/CT in the localization of a hyperfunctioning parathyroid gland in primary hyperparathyroidism. Nucl Med Commun. 2018; 39(11):989-994. DOI: 10.1097/MNM.0000000000000899. View

15.

Fine E . Parathyroid imaging: its current status and future role. Semin Nucl Med. 1987; 17(4):350-9. DOI: 10.1016/s0001-2998(87)80026-0. View

16.

Boudousq V, Guignard N, Gilly O, Chambert B, Mamou A, Moranne O . Diagnostic Performance of Cervical Ultrasound, Tc-Sestamibi Scintigraphy, and Contrast-Enhanced F-Fluorocholine PET in Primary Hyperparathyroidism. J Nucl Med. 2021; 63(7):1081-1086. DOI: 10.2967/jnumed.121.261900. View

17.

Wong K, Fig L, Gross M, Dwamena B . Parathyroid adenoma localization with 99mTc-sestamibi SPECT/CT: a meta-analysis. Nucl Med Commun. 2015; 36(4):363-75. DOI: 10.1097/MNM.0000000000000262. View

18.

Carneiro-Pla D, Solorzano C, Lew J, Irvin 3rd G . Long-term outcome of patients with intraoperative parathyroid level remaining above the normal range during parathyroidectomy. Surgery. 2008; 144(6):989-93. DOI: 10.1016/j.surg.2008.08.026. View

19.

Irvin 3rd G, Carneiro D, Solorzano C . Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg. 2004; 239(5):704-8. PMC: 1356279. DOI: 10.1097/01.sla.0000124448.49794.74. View

20.

Mihai R, Simon D, Hellman P . Imaging for primary hyperparathyroidism--an evidence-based analysis. Langenbecks Arch Surg. 2009; 394(5):765-84. DOI: 10.1007/s00423-009-0534-4. View